CLONING OF THE DOPAMINE D1 RECEPTOR FAMILY

Information

  • Research Project
  • 2248077
  • ApplicationId
    2248077
  • Core Project Number
    R44MH048240
  • Full Project Number
    5R44MH048240-03
  • Serial Number
    48240
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1990 - 34 years ago
  • Project End Date
    8/31/1993 - 31 years ago
  • Program Officer Name
  • Budget Start Date
    9/30/1992 - 32 years ago
  • Budget End Date
    8/31/1993 - 31 years ago
  • Fiscal Year
    1992
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/30/1992 - 32 years ago

CLONING OF THE DOPAMINE D1 RECEPTOR FAMILY

DESCRIPTION (Adapted from applicant's abstract): Dopamine D1 receptors appear to play a significant role in a number of medically important processes including: control of blood pressure, neurohypophyseal hormone release, retinal neuromodulation, natriuresis, gut motility and secretion, motor movement, emotions, behavior and the perceptual state of mind. In particular the dopaminergic system in the brain has been associated with the neurological and psychiatric disorders such as Parkinson's disease and schizophrenia. These receptors are difficult to study due to their low density and interference by other dopamine receptor sites. Since D1 receptors are important targets for new drug development initiatives, a program to clone these receptors and express them in heterologous expression systems has been taken. These expression systems will then be used as tools for the development of new therapeutic agents. In Phase I of this program, two separate human genes which code for receptors of the dopamine D1 pharmacological class were successfully isolated. One of these two receptors represents the fourth member of the dopamine receptor to be cloned. This receptor is a new member of the G protein-coupled receptor family and represents the first report of a gene encoding a functional G-protein coupled receptor accompanied by a closely related pseudogene. The cloning of this receptor, named D18, provides the first clear demonstration that subtypes of the human dopamine D1 receptors are present. In Phase II, the plan is to search for additional members of this new dopamine receptor family and initiate a drug development program focused on these two closely related human receptors.

IC Name
NATIONAL INSTITUTE OF MENTAL HEALTH
  • Activity
    R44
  • Administering IC
    MH
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    SSS
  • Study Section Name
  • Organization Name
    SYNAPTIC PHARMACEUTICAL CORPORATION
  • Organization Department
  • Organization DUNS
  • Organization City
    PARAMUS
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    07652
  • Organization District
    UNITED STATES